Kahraman, SedaErul, EnesSeyyar, MustafaGumusay, OzgeBayram, ErtugrulDemirel, Burcin CakanSendur, Mehmet Ali Nahit2025-05-102025-05-1020231479-66941744-830110.2217/fon-2022-12872-s2.0-85159731947https://doi.org/10.2217/fon-2022-1287https://hdl.handle.net/20.500.14720/10409Kahraman, Seda/0000-0002-5328-6554; Bayoglu, Ibrahim Vedat/0000-0002-0481-1084; Sahin, Elif/0000-0002-1976-3951; Er, Muhammed Muhiddin/0000-0002-0583-0295; Teker, Fatih/0000-0003-4693-6587; Bilgin, Burak/0000-0003-1717-8246; Hacibekiroglu, Ilhan/0000-0002-0333-7405; Yavuzsen, Tugba/0000-0001-9375-8133; Dulgar, Ozgecan/0000-0002-0678-4024; Keskinkilic, Merve/0000-0002-3342-3144; Kayikcioglu, Erkan/0000-0002-7401-5446; Aydin, Esra/0000-0003-0210-3153; Oyucu Orhan, Sibel/0000-0001-8217-3471; Bayram, Ertugrul/0000-0001-8713-7613; Erul, Enes/0000-0002-2487-2087; Aydin, Dincer/0000-0002-7433-3591Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Methods: The authors report retrospective real-life data for 600 patients with estrogen receptor- and/or progesterone receptor-positive and HER2-negative metastatic breast cancer who were treated with ribociclib and palbociclib in combination with letrozole. Results & conclusion: The results demonstrated that the combination of palbociclib or ribociclib with letrozole has similar progression-free survival and overall survival benefit in real life for the patient group with similar clinical features. Specifically, endocrine sensitivity may be a factor to be considered in the treatment preference.eninfo:eu-repo/semantics/closedAccessCdk 46 InhibitorsHer2-Negative Metastatic Breast CancerHr-PositiveLetrozoleArticleQ3Q337133230WOS:000991646700001